# Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

> **NCT06643000** · NA · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Leptomeningeal Metastasis
- EGFR Gene Mutation

## Interventions

- **DRUG:** furmonertinib

## Key facts

- **NCT ID:** NCT06643000
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-05-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643000, "Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06643000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*